secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2024-06-13T23:59:59+00:00
Accession:  0001213900-24-052234
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra completes enrollment in Phase 3 dry eye trial of reproxalap; results expected in Q3 2024
--------------------------------------------------------------------------------

- Phase 3 dry eye chamber trial of 0.25% reproxalap enrolled 132 patients; primary endpoint is ocular discomfort.
- Topline results expected in Q3 2024; NDA resubmission planned for H2 2024 contingent on positive data.
- If approved, reproxalap may be first dry eye drug labeling chronic/acute symptom improvement and ocular redness reduction.
- Four prior chamber trials showed reproxalap statistically superior to vehicle on ocular discomfort (p=0.0003).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024052234/0001213900-24-052234-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000121390024052234/ea0207791-8k_aldeyra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-052234

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer